Viedoc chosen by OSE Immunotherapeutics to run its first COVID-19 vaccine clinical study

Stockholm, Sweden – February 16, 2021 – Viedoc Technologies AB announced today a collaboration with OSE Immunotherapeutics in the struggle to find a COVID-19 vaccine.

Once again, the Viedoc eClinical suite is the preferred platform for running COVID-19 vaccine trials. OSE Immunotherapeutics has long been a Viedoc Technologies' client, so the collaboration was natural. This Phase I/II COVID-19 study with OSE’s COVID-19 vaccine CoVepiT will be conducted in EU at various clinical sites subject to receiving regulatory authorizations.

The Viedoc eClinical suite will be used by OSE to help accelerate the development of its CoVepiT vaccine program. The suite includes Viedoc Clinic (the core of the EDC system), Viedoc Admin for easy administration of sites and staff, including ViedocMe (patient diary and outcomes assessment), Viedoc Logistics (drug management), and eLearning, among many others.  

We are excited to announce this continued collaboration with OSE. Despite continuous progress in the fight against COVID-19, it is vital to continue to develop a variety of vaccines. We are proud to be a part of this struggle together with OSE. — says Henrik Blombergsson, COO of Viedoc Technologies. 

We thank Viedoc for their collaboration in this important clinical trial for OSE Immunotherapeutics, says Alexis Peyroles, CEO of OSE Immunotherapeutics. Continuing: we have always been pleased to work with Viedoc and appreciate such a partnership in clinical development for their continuous, high-quality level and flexibility.

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

Viedoc Technologies is a dedicated developer of eClinical systems by people from the Life Science industry. Today, its clients are clinical research organizations, pharmaceutical, medical device companies, and research institutions working to enhance the lives of millions of people around the world every day.